Jun 11, 2019 / 03:00PM GMT
Terence C. Flynn - Goldman Sachs Group Inc., Research Division - MD
Good morning, everybody. Thanks for joining us. I'm Terence Flynn, the biopharma analyst at Goldman Sachs. Very pleased to welcome you this morning to our first session with Bristol-Myers. Joining us from the company is Chris Boerner, Executive Vice President and Chief Commercial Officer.
Before we get started, I just have to read a quick disclaimer. We're required to make certain disclosures in public appearances about Goldman Sachs' relationships with companies that we discuss. The disclosures relate to investment banking relationships, compensation received, or 1% or more ownership. We are prepared to read aloud disclosures for any issuer upon request. However, these disclosures are available in our most recent reports available to U.S. clients on our firm portals. Disclosures and updates to those disclosures are also available by ticker on the firm's public website. Also the views stated by non-Goldman Sachs personnel do not necessarily reflect those of Goldman Sachs.
Great. Well, thanks so much, Chris, for joining
Bristol-Myers Squibb Co at Goldman Sachs Global Healthcare Conference Transcript
Jun 11, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers